ImmunoGen, Inc. Announces Conference Call to Discuss Its First Quarter Fiscal Year 2015 Financial Results
October 10 2014 - 10:30AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a
biotechnology company that develops novel anticancer therapeutics
using its antibody-drug conjugate (ADC) technology, today announced
that the Company will host a conference call at 8:00 a.m. ET on
Friday, October 24, 2014, to discuss ImmunoGen's financial results
for the three-month period ended September 30, 2014, the first
quarter of its 2015 fiscal year. Management will also provide an
update on the Company.
To access the live call by phone, dial 913-312-0384; the
conference ID is 9325211. The call also may be accessed through the
Investor Information section of the Company's website,
www.immunogen.com. Following the live webcast, a replay of the call
will be available at the same location through November 7,
2014.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The
Company’s ADC technology uses tumor-targeting antibodies to deliver
an ImmunoGen cell-killing agent specifically to cancer cells; the
Company has also developed antibodies with anticancer activity of
their own. The first product approved with ImmunoGen’s ADC
technology is Roche’s Kadcyla®. ImmunoGen has three wholly owned
product candidates in clinical testing with additional compounds in
the clinic through the Company’s partnerships with Amgen, Bayer
HealthCare, Biotest and Sanofi. More information about ImmunoGen
can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, Inc., a member
of the Roche Group.
For Investors:ImmunoGen, Inc.Carol Hausner,
781-895-0600info@immunogen.comorFor Media:Pure Communications,
Inc.Dan Budwick, 973-271-6085
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024
